Search

A recent study conducted by the Naval Medical Research Unit explored the use of tranexamic acid as an adjunct to resuscitative endovascular balloon occlusion of the aorta (REBOA) in a porcine model of hemorrhage. The research aimed to assess whether the combination of tranexamic acid and REBOA would worsen coagulation outcomes and organ damage. The results indicated that the administration of tranexamic acid with REBOA did not lead to more adverse coagulation outcomes, suggesting that non-compressible torso hemorrhage can be safely treated with both methods without exacerbating clotting issues. The study was funded by the Defense Health Program and published in Trauma Surgery & Acute Care Open. [Extracted from the article]

A study conducted at Mayo Clinic investigated the effectiveness of topical tranexamic acid (TXA) in reducing hematoma and seroma formation in breast surgery. The research included six studies with 823 patients and 1477 breasts, showing a significant reduction in hematoma rates in patients who underwent mastectomy but no significant effect on other outcomes. The researchers concluded that larger studies are needed to fully establish the role of topical TXA in optimizing breast surgery outcomes. For more information, the full article can be accessed for free at the publisher's website. [Extracted from the article]

Researchers from Evangelismos General Hospital in Athens, Greece, conducted a systematic review on the use of tranexamic acid (TXA) in bariatric surgery to reduce bleeding complications. The study found that TXA is an effective and safe option for managing bleeding in metabolic surgery, particularly after sleeve gastrectomy. The research, published in Bariatric Surgical Practice and Patient Care, highlights the importance of addressing postoperative bleeding in bariatric surgery to improve patient outcomes. [Extracted from the article]

Researchers at Hamadan University of Medical Sciences conducted a study on the effects of tranexamic acid (TXA) dissolved in warm, cold, and room-temperature irrigation fluids during transurethral resection of the prostate (TURP) surgery. The study aimed to reduce bleeding and postoperative complications, such as shivering, in 100 patients. Results showed that combining TXA in cold irrigation fluid reduced intraoperative bleeding but increased postoperative shivering compared to other groups. The study was a double-blind, randomized clinical trial published in the African Journal of Urology. [Extracted from the article]

A recent study conducted at Guilan University of Medical Sciences in Rasht, Iran, focused on the effects of intravenous tranexamic acid (TXA) on bleeding during burn surgery. The double-blinded, randomized clinical trial involved 94 severe burn patients and found that TXA administration led to significant reductions in blood loss, IV fluid volume, operating room time, length of hospital stay, and transfusions. The study concluded that TXA can effectively reduce bleeding, minimize fluid and blood transfusion needs, and shorten surgery duration, ultimately improving surgical outcomes for burn patients. [Extracted from the article]

A study conducted at the Children's Cancer Hospital in Cairo, Egypt, focused on the use of intraoperative tranexamic acid (TXA) infusion in pediatric limb-salvage surgeries to reduce perioperative blood loss. The trial involved 48 participants under 18 years old with malignant bone tumors of the femur. Results showed that TXA infusion significantly reduced perioperative blood loss and transfusion requirements without causing adverse events, indicating its safety and efficacy in this context. The research was published in the Journal of Bone and Joint Surgery and has been peer-reviewed, providing valuable insights for pediatric surgical practices. [Extracted from the article]

A clinical trial, NCT06780644, is being conducted to compare the effectiveness and safety of two triple combination creams in treating melasma. The study aims to evaluate the use of a cream containing flucinolone acetonide, hydroquinone, and tretinoin against a cream containing mometasone furoate, hydroquinone, and tretinoin. The trial involves 56 female participants aged 30-59 with melasma, and the primary completion date is set for May 26, 2025. The study will assess various outcomes related to melasma severity, quality of life, and melanin levels over a 12-week period. [Extracted from the article]

The article discusses a clinical trial, NCT06763367, focusing on the efficacy and safety of a Centella Asiatica-infused facial mask in treating skin diseases. The study utilized a randomized double-blind method, with each cheek randomly assigned to receive either the Centella Asiatica mask or a control group. The trial aims to evaluate outcomes such as Clinical Erythema Score, Global Aesthetic Improvement Scale Score, and Melasma Area and Severity Rating. The study is not yet recruiting participants and is set to conclude on November 30, 2026. [Extracted from the article]

Researchers at the Medical College of Wisconsin conducted a retrospective review on intraoperative factors affecting pain management and postoperative narcotic use in cranial vault remodeling. The study found that factors such as total fluid volume infused, operative times, blood products transfused, and the use of drains and medications were associated with varying levels of narcotic use. Modifying these intraoperative factors could potentially lead to decreased postoperative pain and reduced narcotic use, improving overall outcomes for patients undergoing open cranial vault reconstruction. The research was published in the Journal of Craniofacial Surgery and has been peer-reviewed. [Extracted from the article]

A study conducted at Ospedale Regionale di Lugano in Switzerland evaluated the effects of systemic tranexamic acid administration on postoperative complications in patients undergoing reduction mammaplasty. The study found that tranexamic acid significantly reduced postoperative bleeding, drainage volume, and length of hospital stay compared to the control group. Researchers concluded that tranexamic acid is well-tolerated and should be widely used in plastic surgery to facilitate quicker postoperative recovery. [Extracted from the article]

Researchers at Shanxi Provincial People's Hospital conducted a study to determine the optimal dose of intravenous tranexamic acid (TXA) for reducing blood loss in spinal surgery. The study included 24 randomized controlled trials and found that all TXA treatments were more effective than a placebo in reducing blood loss. The highest dose of TXA (100 mg/kg + 10 mg.kg/h) showed the most significant benefits, but safety considerations for higher doses are essential. The research highlights the effectiveness of intravenous TXA in reducing blood loss during multilevel spine surgery. [Extracted from the article]

A recent study from BLDE University explores the use of tranexamic acid (TXA) via intravenous and irrigation fluid routes to control bleeding during transurethral resection of the prostate (TURP). The study involved 105 cases and found that TXA reduced postoperative blood loss, with both administration routes showing similar efficacy. The research concluded that TXA is safe and effective in reducing blood loss during TURP procedures. [Extracted from the article]

A new report from Christian Medical College and Hospital in Ludhiana, India, discusses research findings on cerebral hemorrhage and the potential benefits of using Tranexamic acid (TXA) to reduce early mortality in patients. The Indian Trial of Tranexamic acid in Spontaneous Intracerebral Hemorrhage study protocol aims to enroll 3400 patients to assess the efficacy of TXA in reducing mortality at day 30, as well as other outcomes such as radiological reduction in hematoma volume and neurological impairment. If proven effective, TXA could significantly impact the medical management of intracerebral hemorrhage. The study is registered with Clinical Trial Registry India and Clinical Trials.gov. [Extracted from the article]

Researchers from the University of Missouri conducted a systematic review and meta-analysis on the failure rates of conservative management of minimally symptomatic chronic subdural hematoma (cSDH). The study analyzed data from 35 studies involving 2095 patients and found that 19.82% of patients required rescue surgery. The research suggested that corticosteroids or atorvastatin may have potential benefits in reducing the failure rate, but the overall effectiveness of these interventions remains uncertain. The study was peer-reviewed and can be accessed through World Neurosurgery. [Extracted from the article]

A recent study conducted at the University of Melbourne focused on the use of tranexamic acid (TXA) in hip and spine surgeries for children with cerebral palsy (CP). The research aimed to provide an overview of the available literature on TXA in these surgeries, highlighting the variability in dosing and outcomes. While TXA was generally considered safe, there was mixed evidence on its efficacy, with a lack of postoperative administration noted in the studies reviewed. The study emphasized the need for further research in this area, particularly regarding optimal dosing and timing of TXA administration. [Extracted from the article]

A recent study conducted at Sao Joao University Hospital in Porto, Portugal, explored the impact of tranexamic acid (TXA) administration in reduction mammaplasty procedures. The study included 7 studies involving 1234 female patients, with 60% receiving TXA. Results showed benefits such as reduced drain fluid output and hematoma risk with the use of TXA, suggesting its effectiveness and safety in reduction mammaplasty. The research was published in the Annals of Plastic Surgery and can be accessed for further information. [Extracted from the article]

A recent study from the University of Wuerzburg in Germany examined the combined effects of tranexamic acid (TXA) and vancomycin powder (VP) on human chondrocytes in vitro. The research found that prolonged exposure to TXA and VP reduced cell viability and proliferation rates, but did not affect the expression of chondrogenic marker genes. Limiting the exposure time to 24 hours may be considered safe, but further research is needed to fully understand the effects of these substances on periarticular cell types in total knee arthroplasty (TKA). [Extracted from the article]

A recent study conducted at Philipps-University Marburg in Germany sheds light on Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's Disease. HHT is a systemic disease that can significantly impact quality of life and often goes undiagnosed for an average of two decades. The study emphasizes the importance of early diagnosis, interdisciplinary treatment, and awareness of the condition to improve outcomes for individuals with HHT. Nosebleeds are a common symptom of HHT, and outpatient measures such as nasal packing and medication can help manage this symptom. [Extracted from the article]

Researchers from Kaohsiung Chang Gung Memorial Hospital conducted a retrospective study on the association between intravenous (IV) and topical tranexamic acid (TXA) use and periprosthetic joint infections (PJI) in hip and knee arthroplasty patients. The study included 8042 patients who underwent total joint arthroplasty, comparing those who received TXA to those who did not. The results showed that perioperative TXA administration was linked to a lower incidence of PJI, reduced blood transfusion rates, and shorter hospital stays, with both IV and topical TXA routes demonstrating similar effectiveness, especially in primary total knee arthroplasty. [Extracted from the article]

A research study conducted at King Faisal University in Saudi Arabia compared the efficacy of high-dose versus low-dose tranexamic acid (TXA) in reducing blood loss during adolescent idiopathic scoliosis (AIS) surgery. The study, which included four research papers published between 2009 and 2022 and a total of 531 patients, found that high-dose TXA was more effective in reducing blood loss compared to low-dose TXA. The researchers concluded that further clinical trials with larger sample sizes are needed to confirm these results and determine optimal dosing regimens for maximizing efficacy while ensuring safety. [Extracted from the article]

A recent study conducted by researchers at the Sichuan Provincial Orthopedic Hospital focused on the use of tranexamic acid (TXA) in total shoulder arthroplasty (TSA). The study, which included 372 patients from various sources, found that TXA significantly reduced blood loss volume, drain out, and postoperative change in hemoglobin levels. The researchers concluded that TXA administration in TSA can effectively reduce blood loss. Further research with larger sample sizes is recommended to explore the safety and efficacy of TXA in shoulder arthroplasty. [Extracted from the article]

Researchers from the Icahn School of Medicine at Mount Sinai conducted a study on the impact of intraoperative intravenous tranexamic acid (IV TXA) on bleeding events in gender-affirming vaginoplasty patients. The study included 628 patients, with 357 receiving IV TXA and 271 not receiving it based on surgeon preference. Results showed that IV TXA use was associated with significantly fewer hematoma cases, minor hematomas, postoperative major bleeding, and readmission for bleeding. The research concluded that IV TXA reduced bleeding events and complications in gender-affirming vaginoplasty patients, providing valuable insights for medical practitioners in this field. [Extracted from the article]

Researchers at the University of Colorado have published new data on personalized medicine, specifically focusing on navigating hemorrhagic shock. The study highlights the complexity of inflammatory responses, biomarker utility, and evidence-based therapeutic interventions in managing hemorrhagic shock. The research emphasizes the importance of tailored therapeutic approaches, early hemorrhage control, appropriate blood product ratios, and time-sensitive interventions for improved patient outcomes. Future directions include developing precision medicine approaches, real-time monitoring systems, and novel therapeutic modalities to address challenges in personalized treatment strategies for hemorrhagic shock. [Extracted from the article]

A recent study conducted at Hokkaido University Hospital in Sapporo, Japan, focused on the efficacy of coagulation factor concentrates in managing trauma-induced coagulopathy (TIC). The research included randomized and non-randomized controlled trials and found that while fibrinogen concentrate (FC), prothrombin coagulation cofactor (PCC), and combination administrations of FC and PCC did not significantly reduce mortality rates, they did reduce transfusion rates and complications in patients with coagulopathy-associated trauma. The study highlighted the need for a universal definition of TIC and called for further well-constructed trials to investigate the efficacy of blood component products, specifically FC and PCC supplementation for TIC. [Extracted from the article]

Researchers at Korea University conducted a study on the clinical effects of using tranexamic acid during minimally invasive scoliosis surgery for adolescent idiopathic scoliosis. The study involved 97 patients and found that the use of tranexamic acid significantly reduced the need for blood transfusions and postoperative complications. The research concluded that tranexamic acid was effective in minimizing blood loss and improving surgical outcomes in minimally invasive scoliosis surgery. [Extracted from the article]

A recent study conducted by researchers at Airlangga University in Surabaya, Indonesia, compared the efficacy of intradermal tranexamic acid and topical triple combination modification in treating melasma. The study found that intradermal tranexamic acid was more effective in reducing the severity of melasma and had fewer side effects compared to the topical treatment. This research suggests that intradermal tranexamic acid could be a promising primary therapy option for individuals with melasma. [Extracted from the article]

Researchers from Shenyang Pharmaceutical University have developed a new approach to enhance sclerotherapy for vascular malformations, a common issue affecting infants. The study focused on creating a dual-mechanism gel that could effectively treat vascular malformations with high efficiency and low toxicity. By combining a cationic surfactant sclerosant with a PLA inhibitor, the gel could promote vascular fibrosis and reduce the risk of drug entering non-targeted sites. This research provides a precise and innovative method for treating vascular sclerosis, offering potential benefits for patients' health and quality of life. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences conducted a study comparing the effects of oral and intravenous tranexamic acid on intra-operative bleeding during endoscopic sinus surgery. The study involved 48 patients who were randomly assigned to different groups receiving varying doses of tranexamic acid or a control group. The results showed that systemic tranexamic acid administration improved surgical field quality, reduced bleeding, and shortened operation duration without significant differences in hematocrit levels or side effects. This research was published in the Archives of Anesthesia and Critical Care and was conducted by Majid Razavi and colleagues from Mashhad, Iran. [Extracted from the article]

A report from the Dallas Plastic Surgery Institute discusses the clinical applications of Tranexamic Acid (TXA) in plastic and reconstructive surgery. The study reviews evidence supporting the use of TXA in various plastic surgical procedures, highlighting its role in reducing blood loss and transfusion requirements in craniofacial surgery and cosmetic surgery. The research emphasizes the need for further studies to determine TXA's effects in other procedures such as face-lift surgery and microsurgery. Standardized measurements are recommended to quantify TXA's impact on ecchymoses and edema in cosmetic surgery. [Extracted from the article]

A recent study conducted at the University of Ilorin Teaching Hospital in Nigeria focused on the effectiveness of tranexamic acid in controlling bleeding during transurethral benign prostatic hyperplasia surgery. The research, funded by the Commonwealth Shared Scholarship Commission and Edinburgh University, found that tranexamic acid can reduce blood loss and minimize changes in hemoglobin levels during the procedure. However, the study concluded that tranexamic acid does not decrease the need for blood transfusions or shorten hospital stays. Further evaluation is needed to determine the utility of tranexamic acid in low-resource settings where advanced haemostatic techniques may not be readily available. [Extracted from the article]

Researchers from China Medical University and Hospital conducted a meta-analysis on the clinical efficacy of cysteamine application for treating melasma, a hyperpigmentary disorder. The study found that cysteamine, a tyrosinase inhibitor, showed depigmenting effects in patients resistant to standard treatments. However, the research concluded that cysteamine's depigmentation effect was comparable to other treatments like hydroquinone-based regimens and tranexamic acid mesotherapy. The study suggested that using cysteamine in patients with a shorter duration of melasma may result in better efficacy. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers at Imam Abdulrahman Bin Faisal University in Saudi Arabia focused on the effectiveness and safety of Tranexamic Acid (TXA) in treating aneurysmal subarachnoid hemorrhage (SAH). The study, which included six randomized controlled trials involving 2990 patients, found that TXA significantly reduced the risk of rebleeding in SAH patients. However, there were no significant differences in mortality rates or thromboembolic complications between the TXA group and the control group. The researchers concluded that while TXA can effectively lower rebleeding risk, further research is needed to assess its long-term impacts and optimize its clinical use. [Extracted from the article]

The article discusses the significance of ultra-early hematoma expansion in primary intracerebral hemorrhage (ICH) and its impact on clinical outcomes. The study analyzed data from the STOP-MSU trial, finding that ultra-early hematoma expansion is associated with ongoing hematoma growth, poor functional outcomes, and increased mortality. The research suggests that hyperacute hematoma expansion could be a target for therapeutic intervention, although tranexamic acid treatment did not show a significant effect on ultra-early hematoma expansion. [Extracted from the article]

A Phase II clinical trial, NCT06718751, is being conducted to evaluate the safety and efficacy of using Tranexamic Acid (TXA) therapy to treat chronic subdural hematomas (cSDH) without surgery. Patients not requiring surgery for cSDH will be randomly assigned to receive either TXA or a placebo for 21 weeks, with monitoring through neurological testing and imaging. The study aims to assess the resolution of cSDH and functional outcomes, with primary completion expected by September 30, 2025. This research is being led by Baylor College of Medicine and focuses on improving clinical outcomes for patients with cSDH. [Extracted from the article]

Researchers from the Keck School of Medicine of the University of Southern California conducted a study to investigate the use of tranexamic acid (TXA) in total joint arthroplasty (TJA) patients receiving apixaban for thromboprophylaxis. The study found that patients who received both apixaban and TXA had a reduced risk of bleeding complications without increasing thromboembolic risk. The researchers recommend considering the perioperative administration of TXA for TJA patients receiving apixaban to improve outcomes. [Extracted from the article]

A study conducted at the Swedish Neuroscience Institute in Seattle, Washington, focused on neurosurgical bleeding in patients with platelet storage pool disorders, specifically dense-granule deficiency (DGD). The research highlighted the challenges in managing intracranial neurosurgery in patients with inherited platelet disorders and emphasized the importance of thoughtful hemostatic planning and interventions such as platelet transfusions and tranexamic acid to prevent recurrent bleeding. The study provides valuable insights into the clinical management of intracranial tumor surgery and Cyberknife radiosurgery in patients with DGD. [Extracted from the article]

The article from Hematology Week discusses the perioperative considerations in pediatric patients with congenital and acquired coagulopathy. It highlights the risks faced by neonates, infants, and children undergoing major surgery or trauma due to potential severe coagulopathy. The research emphasizes the importance of individualized treatment strategies, such as viscoelastic testing and targeted therapies like tranexamic acid or blood component transfusions, in managing perioperative bleeding in pediatric patients with coagulopathy. The study suggests expert consensus be considered until further research validates goal-directed perioperative bleeding management in this population. [Extracted from the article]

A study conducted at Nankai University in China evaluated the effects of tranexamic acid (TXA) in preventing postpartum hemorrhage (PPH) among women with identified risk factors for PPH during vaginal delivery. The study, which enrolled 2258 women, found that while TXA did not significantly reduce the overall incidence of PPH compared to a placebo, it was associated with a significantly lower incidence of severe PPH. Additionally, women who received TXA had a reduced need for additional uterotonic agents. The research was supported by the National Key Research And Development Program and the Tianjin Health Research Project. [Extracted from the article]

Researchers from King Saud bin Abdulaziz University for Health Sciences conducted a meta-analysis and systematic review of randomized controlled trials to evaluate the efficacy of tranexamic acid (TXA) in treating melasma. The study included 22 relevant studies with 1280 patients and found that TXA significantly reduced melasma severity when administered orally, topically, or via injection. Despite the positive results, further research is needed to standardize TXA administration methods and address long-term effects, as well as to establish more consistent treatment protocols due to high heterogeneity observed in the studies. [Extracted from the article]

A recent study from Brown University in Providence, Rhode Island, explores techniques to optimize visualization in shoulder arthroscopy, a surgical procedure that has advanced the understanding and management of shoulder conditions. The research emphasizes the importance of improving visualization through various methods such as patient positioning, mechanical debridement, and controlled hypotensive anesthesia. The study underscores the need for a comprehensive understanding of the evidence supporting these techniques to enhance their clinical utility. For more information, readers can refer to the Journal of the American Academy of Orthopaedic Surgeons. [Extracted from the article]

Researchers at Shenzhen Technology University have developed alkyl ester derivatives of Tranexamic Acid (TA) to enhance skin delivery for treating melasma and hyperpigmentation. The study found that TA4 and TA8 significantly improved skin penetration and deposition compared to unmodified TA, with rapid hydrolysis to release the parent drug. Safety assessments showed no significant skin irritation or cytotoxicity, making the hydrogel formulation a promising candidate for topical application. The research suggests that alkyl esterification prodrug design is a promising approach to enhance the skin delivery of TA. [Extracted from the article]

A recent study conducted by a researcher at Hamad Medical Corporation in Doha, Qatar, focused on the use of Tranexamic acid (TXA) in facial aesthetic surgeries. The study, which included data from 14 systematic reviews and meta-analyses, found that TXA can effectively reduce blood loss volume and duration of surgery in procedures such as rhinoplasty, septorhinoplasty, rhytidectomy, and blepharoplasty. While the research suggests that TXA can help minimize complications during and after facial aesthetic surgeries, further studies are needed to establish standardized protocols for assessing outcomes. For more information, the full article can be accessed through the Aesthetic Surgery Journal Open Forum published by Oxford University Press. [Extracted from the article]

A recent study from the University of Oxford evaluated the efficacy of Tranexamic Acid (TXA) in reducing blood loss during orthognathic surgery. The study included 15 studies with a total of 1060 patients and found that TXA significantly reduced intraoperative blood loss, Hb level drop, and improved surgical field visibility. The researchers concluded that TXA effectively minimizes blood loss in orthognathic surgery, but suggest further studies to solidify the evidence. The study was published in the British Journal of Oral and Maxillofacial Surgery and can be accessed online. [Extracted from the article]

A recent study conducted at Liaquat National Hospital and Medical College examined the efficacy and safety of tranexamic acid in managing chronic subdural hematoma (CSDH). The meta-analysis included six studies with 2024 participants and found that tranexamic acid may reduce CSDH recurrence, although the significance varied across studies. Adverse effects with tranexamic acid were similar to controls, suggesting a potential role for tranexamic acid in CSDH management, but larger trials are needed for confirmation. [Extracted from the article]

Researchers at the All India Institute of Medical Sciences (AIIMS) conducted a study on breast cancer patients undergoing axillary lymph node dissection (ALND) to address the issue of excess and prolonged axillary drainage. The study focused on the efficacy of perioperative systemic tranexamic acid along with topical hemocoagulase in decreasing axillary drain output. The research aimed to reduce the cumulative axillary drain output and shorten the requirement of drainage after ALND compared to a placebo, with the findings being peer-reviewed and published in the World Journal of Surgery. [Extracted from the article]

A recent study conducted at the University of Oxford focused on the use of Tranexamic Acid (TXA) in rhinoplasty and septoplasty procedures to reduce perioperative bleeding. The research, which included 11 randomized controlled trials with 968 patients, found that TXA significantly decreased intraoperative blood loss and improved surgeon satisfaction. The study concluded that TXA is effective in reducing blood loss during these procedures, with high-quality evidence supporting its efficacy. [Extracted from the article]

A study conducted at Universita della Svizzera Italiana in Lugano, Switzerland, explored the effects of systemic tranexamic acid administration on drainage volume, duration of drain placement, and length of hospital stay in patients undergoing skin- and nipple-sparing mastectomies with immediate expander-based breast reconstruction. The research involved 132 patients and found that tranexamic acid significantly reduced drainage volume, shortened the duration of drain placement, and decreased the length of hospital stay without significant side effects. The study suggests that systemic tranexamic acid administration could be a safe and beneficial option for patients undergoing these types of mastectomies. [Extracted from the article]

A recent study conducted at University College Hospital focused on the impact of early tranexamic acid treatment on fatigue in patients with mild traumatic brain injury (mTBI). The study, which analyzed data from the CRASH-3 trial, found no evidence that tranexamic acid reduces fatigue in mTBI patients. The results, while inconclusive, suggest the need for further research to validate these findings. For more information on this research, readers can refer to the Wellcome Open Research journal article. [Extracted from the article]

A study conducted at University Hospital Cleveland compared the outcomes of same-day discharge (SDD) and inpatient (IP) total shoulder arthroplasty (TSA) procedures, focusing on different age groups. The research found that SDD TSA had a shorter length of stay without increasing complications, emergency department visits, readmissions, or reoperations. The study concluded that TSA can be safely performed in an outpatient setting, even for older patients, without increasing complication rates. [Extracted from the article]